Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer

Bioconjugate Chemistry

Volumn 18, Issue 4, 2007, Pages 1205-1212

  Borbas, K Eszter ^a,c   Ferreira, Catia S M ^a,d   Perkins, Alan ^b   Bruce, James I ^a   Missailidis, Sotiris ^a  

^a OPEN UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; DISEASES; LIGANDS; METAL COMPLEXES; MONOCLONAL ANTIBODIES; RADIOTHERAPY; TUMORS;

ANTIBODY-FRAGMENT; APTAMERS; DIAGNOSTIC IMAGING; MONOMERICS; MULTIMERIC; SIDE EFFECT; TARGETED RADIOTHERAPY; TUMOR IMAGING; TUMOR MARKERS; TUMOR RADIOTHERAPY;

CHELATION;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; APTAMER; CHELATING AGENT; LIGAND; MERTIATIDE TC 99M; METAL COMPLEX; MONOCLONAL ANTIBODY; MONOMER; MUCIN 1; POLYMER; RADIOPHARMACEUTICAL AGENT; SULFUR DERIVATIVE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; COMPLEX FORMATION; DIAGNOSTIC IMAGING; DRUG CONJUGATION; DRUG DESIGN; DRUG SYNTHESIS; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; IMMUNOGENICITY; ISOTOPE LABELING; MOUSE; NONHUMAN;

EID: 34547166934     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0700741     Document Type: Article

References (44)

1. von Mensdorff-Pouilly, S., Snijdewint, F. G. M., Verstraeten, A. A., Verheijen, R. H. M., and Kenemans, P. (2000) Human MUC1 mucin: a multifaceted glycoprotein. Int. J. Biol. Markers 15, 343-356.
2. Zotter, S., Hageman, P. C., Lossnitzer, A., Mooi, and W. J., Hilgers (1988) J. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev. 11-12, 55-101.
3. Dent, G. A., Civalier, C. J., Brecher, M. E., and Bentley, S. A. (1999) MUC1 expression in hematopoietic tissues. Am. J. Clin. Pathol. 111, 741-747.
4. Packer, L. M., Williams, S. J., Callaghan, S., Gotley, D. C., and McGuckin, M. A. (2004) Expression of the cell surface mucin gene family in adenocarcinomas. Int. J. Oncol. 25, 1119-1126.
5. Burchell, J., Wang, D., and Taylor-Papadimitriou, J. (1984) Detection of the tumour-associated antigens recognized by the monoclonal antibodies HMFG-1 and 2 in serum from patients with breast cancer. Int. J. Cancer 34, 763-768.
6. Tomlinson, I. P. M., Whyman, A., Barrett, J. A., and Kremer, J. K. (1995) Tumour marker CA15-3: Possible uses in the routine management of breast cancer. Eur. J. Cancer 31A, 899-902.
7. Nicolini, A., Carpi, A., Michelassi, C., Spinelli, C., Conte, M., Miccoli, P., Fini, M., and Giardino, R. (2003) "Tumour marker guided" salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. Biomed. Pharmacother. 57, 452-459.
8. Bon, G. G., van Kamp, G. J., Verstraeten, R. A., von Mensdorff-Pouilly, S., Hilgers, J., and Kenemans, P. (1999) Quantification of MUC1 in breast cancer patients. A method comparison study. Eur. J. Obstet. Gynecol. Reprod. Biol. 83, 67-75.
9. Devine, P. L., McGuckin, M. A., Quin, R. J., and Ward, B. G. (1994) Serum markers CASA and CA 15-3 in ovarian cancer: all MUC1 assays are not the same. Tumor Biol. 15, 337-344.
10. Cazin, J. L., Gosselin, P., Boniface, B., Demaille, M. C., and Demaille, A. (1992) An evaluation of CA549, a circulating marker of breast cancer using a procedure for comparision with CA15.3. Anticancer Res. 12, 719-724.
11. Kuralay, F., Tokgöz, Z., and Cömlecki, A. (2000) Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin. Clin. Chim. Acta 300, 43-55.
12. Schuhmacher, J., Kaul, S., Klivényi, G., Junkermann, H., Magener, A., Henze, M., Doll, J., Haberkorn, U., Amelung, F., and Bastert, G. (2001) Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res. 61, 3712-3717.
13. Apostopoulos, V., Pietersz, G. A., Tsibanis, A., Tsikkinis, A., Drakaki, H., Loveland, B. E., Piddlesden, S. J., Plebanski, M., Pouniotis, D. S., Alexis, M. N., McKenzie, I. F., and Vassilaros, S. (2006) Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 8, R27.
14. Richman, C. M., and DeNardo, S. J. (2001) Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. Crit. Rev. Oncol. Hematol. 38, 25-35.
15. Kunkler, R. B., Bishop, M. C., Green, D. J., Pimm, M. V., Price, M. R., and Frier, M. (1995) Targeting of bladder cancer with monoclonal antibody NCRC48 - a possible approach for intravesical therapy. Br. J. Urol. 76, 81-86.
16. Hughes, O. D. M., Bishop, M. C., Perkins, A. C., Frier, M., Price, M. R., Denton, G., Smith, A., Rutherford, R., and Schubiger, P. A. (1997) Preclinical evaluation of copper-67 labeled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer. Eur. J. Nucl. Med. 24, 439-443.
17. Hughes, O. D. M., Bishop, M. C., Perkins, A. C., Wastie, M. L., Denton, G., Price, M. R., Frier, M., Denley, H., Rutherford, R., and Schubiger, P. A. (2000) Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. J. Clin. Oncol. 18, 363-370.
18. 99mTc conjugate for immunos-cintigraphy of bladder cancer. Urol. Res. 29, 13-19.
19. 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer. J. Nucl. Med. 42, 726-732.
20. Gold, D. V., Schutsky, K., Modrak, D., and Cardillo, T. M. (2003) Low-dose radioimmunotherapy (Y-90-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin. Cancer Res. 9, 3929S-3937S.
21. IIIindium-labelled anti-MUC1 mucin monoclonal antibody C595. Br. J. Urol. Int. 87, 39-46.
22. Pestourie, C., Tavitian, B., and Duconge, F. (2005) Aptamers against extracellular targets for in vivo applications. Biochimie 87, 921-930.
23. Tuerk, C., and Gold, L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510.
24. Eulberg, D., and Klussmann, S. (2003) Spiegelmers: biostable aptamers. ChemBioChem 4, 979-983.
25. Kusser, W. (2000) Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution. Rev. Mol. Biotechnol. 74, 27-38.
26. Schmidt, K. S., Borkowski, S., Kurreck, J., Stephens, A. W., Bald, R., Hecht, M., Friebe, M., Dinkelborg, L., and Erdmann, V. A. (2004) Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res. 32, 5757-5765.
27. Hilger, C. S., Willis, M. C., Wolters, M., and Pieken, W. A. (1998) Synthesis of a Tc-99m-labeled, modified RNA. Tetrahedron Lett. 39, 9403-9406.
28. Kuhnast, B., Klussmann, S., Hinnen, F., Boisgard, R., Rousseau, B., Fürste, J. P., Tavitian, B., and Dollé, F. (2003) Fluorine-18- and iodine-125-labelling of spiegelmers. J. Labelled Compd. Radiopharm. 46, 1205-1219.
29. Tavitian, B. (2006) In vivo imaging with oligonucleotides for diagnosis and drug developement. Gut 52 (Suppl IV), iv40-iv47.
30. Hicke, B. J., Stephens, A. W., Gould, T., Chang, Y.-F., Lynott, C. K., Heil, J., Borkowski, S., Hilger, C.-S., Cook, G., Warren, S., and Schmidt, P. G. (2006) Tumor targeting by an aptamer. J. Nucl. Med. 47, 668-678.
31. Lindoy, L. F. (1990) The chemistry of macrocyclic ligand complexes. Cambridge University Press, Cambridge, UK.
32. Ferreira, C. S. M., Matthews, C. S., and Missailidis, S. (2006) DNA aptamers that bind to MUC1 tumour marker: Design and characterization of MUC1-binding single-stranded DNA aptamers. Tumor Biol. 27, 289-302.
33. DeAnda, A., Jr., Coutre, S. E., Moon, M. R., Vial, C. M., Griffin, L. C., Law, V. S., Komeda, M., Leung, L. L., and Miller, D. C. (1994) Pilot-study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann. Thorac. Surg. 58, 344-350.
34. Lee, J. F., Stovall, G. M., and Ellington, A. D. (2006) Aptamer therapeutics advance. Curr. Opin. Chem. Biol. 10, 282-289.
35. Bodanszky, M. (1984) Principles of Peptide Synthesis. Akad Verlag, Berlin.
36. Gokel, G. W. (1992) Lariat ethers: from simple sidearms to supramolecular systems. Chem. Soc. Rev. 21, 39-47.
37. Dilworth, J. R., and Parrott, S. J. (1998) The biomedical chemistry of technetium and rhenium. Chem. Soc. Rev. 27, 43-55.
38. 99mTc brain imaging agents. J. Med. Chem. 28, 1280-1284.
39. 3S-adipate). Bioconjugate Chem. 9, 108-117.
40. Schwartz, M. J., and Lewis, J. H. (1984) Meckel's diverticulum: pitfalls in scintigraphic detection in the adult. Am. J. Gastroenterol. 79, 611-618.
41. Sternberg, E. D., Dolphin, D., and Bruckner, C. (1998) Porphyrin-based photosensitizers for use in photodynamic therapy. Tetrahedron 54, 4151-4202.
42. Lees, J. E., Fraser, G. W., and Dinsdale, D. (1997) Direct beta autoradiography using microchannel plate (MCP) detectors. Nucl Instrum. Methods Phys. Res., Sect. A 392, 349-353.
43. Lees, J. E., and Richards, P. G. (1999) Rapid, high-sensitivity imaging of radiolabeled gels with microchannel plate detectors. Electrophoresis 20, 2139-2143.
44. Lees, J. E., Murray, A., Perkins, A. C., and Fraser, G. W. (2002) Autoradiography of high-energy radionuclides using a microchannel plate detector. IEEE Trans. Nucl. Sci. 49, 153-155.